Ibogaine is taken orally as a single large dose, typically in a medically supervised setting outside the United States, where it remains a Schedule I controlled substance. A standard treatment dose ranges from 15 to 20 mg/kg of body weight, meaning a 75 kg (165 lb) person would take roughly 1,125 to 1,500 mg. Because ibogaine carries serious cardiac risks, the process involves extensive medical screening beforehand, continuous monitoring during the session, and days of recovery afterward. This is not something you take casually or at home.
Legal Status in the U.S. and Abroad
Ibogaine is classified as a Schedule I substance under U.S. federal law, making it illegal to possess or administer. Most people who pursue ibogaine treatment travel to clinics in Mexico, Costa Rica, Portugal, or New Zealand, where it is either legal or unregulated. In 2025, Texas signed a law authorizing FDA-approved clinical trials to study ibogaine for opioid use disorder, depression, and PTSD, with a particular focus on veterans. That law funds research, not public access, so clinical treatment within the U.S. is still not available outside of trial settings.
Medical Screening Before Treatment
The screening process is the most important part of ibogaine treatment, because the substance can cause dangerous changes to heart rhythm. Your body converts ibogaine into a metabolite called noribogaine, which has a plasma half-life of 28 to 49 hours and can prolong the heart’s electrical cycle for several days after a single dose. This means cardiac events can occur not just during the session but days later.
Reputable clinics require a recent electrocardiogram (ECG) to measure your QT interval, the portion of each heartbeat where the heart recharges electrically. If that interval is already prolonged, ibogaine could push it into a dangerous range. Blood tests check liver function, kidney function, and electrolyte levels, especially potassium and magnesium, since imbalances in these minerals have been linked to every known ibogaine fatality. Blood work older than 14 days is generally repeated. A second ECG is taken on arrival to confirm the earlier results.
Urine screening checks for substances that interact dangerously with ibogaine. Clinical trial protocols require negative tests for opioids (including methadone and buprenorphine), benzodiazepines, amphetamines, cocaine, barbiturates, SSRIs, SNRIs, mood stabilizers, and alcohol. If potassium or magnesium levels fall below optimal ranges, supplementation is required before the dose is given.
Medications You Must Stop First
Ibogaine interacts with a wide range of drugs, and the consequences can be fatal. The most critical categories to clear from your system include:
- Opioids: Methadone and buprenorphine must be fully tapered. Some clinics transition patients to short-acting opioids like morphine first, because these clear the body faster. Buprenorphine binds tightly to receptors and can take weeks to wash out.
- SSRIs and SNRIs: Antidepressants that raise serotonin levels must be stopped, typically weeks in advance, because combining them with ibogaine risks serotonin syndrome.
- Benzodiazepines: These must be tapered and cleared before treatment.
- Any drug that prolongs the QT interval or inhibits the liver enzyme CYP2D6: This includes certain antibiotics, antipsychotics, and heart medications. CYP2D6 is the enzyme your liver uses to break down ibogaine, so anything that slows that enzyme raises ibogaine levels in your blood.
Clinical trial protocols require participants to stop all prescription and non-prescription drugs, including herbal supplements, at least two weeks before dosing. In practice, tapering off long-acting opioids or antidepressants can take much longer, and that timeline needs to be planned with medical guidance.
What the Session Looks Like
Ibogaine is swallowed in capsule form, usually on an empty stomach to reduce nausea. The full experience lasts 12 to 36 hours and unfolds in three distinct phases.
The acute visionary phase begins one to three hours after ingestion. For the next four to eight hours, you experience vivid, dreamlike visions with your eyes closed, intensified by a dark, quiet room. This phase is often described as watching scenes from your own life or encountering symbolic imagery. It is not recreational. Nausea and vomiting are common. You may also experience a loud buzzing sound in your ears, extreme sensitivity to noise, difficulty coordinating movement, visual tracers, and a feeling of dissociation from your body. Most people lie still during this phase and cannot walk safely.
The evaluative phase begins roughly 8 to 20 hours after dosing. The visual content fades, replaced by a period of introspection. People report heightened intuition, personal insight, and a sense of reviewing their life patterns with unusual clarity. Physical discomfort generally eases during this phase, though you will still feel heavy and fatigued.
The residual phase starts around 12 to 24 hours after the initial dose and can last an additional 24 to 72 hours. During this period, most people report reduced need for sleep, mental clarity, and a calm emotional state. This is the window where integration begins, processing what came up during the experience.
Monitoring During the Session
In a clinical setting, ECGs are performed every 30 minutes for the first 12 hours to track changes in heart rhythm. Blood pressure and heart rate are measured at each of those intervals as well. If the QT interval stays prolonged beyond certain thresholds (above 450 ms for men, 470 ms for women), monitoring continues hourly. If the interval climbs above 500 ms, the situation becomes medically urgent. This level of cardiac surveillance continues for at least 24 hours after dosing.
Staff also assess coordination and balance using standardized scales, since ibogaine causes significant loss of motor control. Delirium screening tracks whether the person’s mental state is within expected parameters. You will not be left alone during the active phases of the experience.
The Days After Treatment
Because noribogaine stays active in your body for two to four days, the risk period extends well beyond the session itself. Cardiac rhythm changes can persist for several days, which is why reputable clinics keep patients on-site for monitoring rather than discharging them the next morning.
Electrolyte levels, particularly potassium and magnesium, need to remain in optimal ranges during this window. If levels dip below normal, supplementation continues. Physical recovery is gradual. Most people feel drained and need rest for several days, even as they report improved mood and reduced cravings.
For people using ibogaine to interrupt opioid dependence, the days immediately following treatment are critical. Ibogaine can dramatically reduce withdrawal symptoms and cravings, but this effect is not permanent on its own. Ongoing support, whether therapy, peer groups, or structured aftercare, shapes whether the interruption translates into lasting change. The mental clarity many people describe during the residual phase can be a powerful starting point, but it needs to be built on with deliberate effort in the weeks and months that follow.
Why Setting Matters
The majority of ibogaine-related deaths have occurred in unsupervised or poorly monitored settings. The combination of cardiac risk, severe ataxia (you cannot walk or stand safely), intense psychological content, and a multi-day active metabolite makes this one of the highest-stakes psychoactive substances a person can take. The difference between a medically supervised session with continuous ECG monitoring and an informal setting without it is, in some cases, the difference between life and death. If you are considering ibogaine, the quality of the clinical team and their monitoring protocols should be the first thing you evaluate, not the last.